Am J Transplant, Volume 19, Suppl 3 Archives - Page 197 of 214 - ATC Abstracts

2019 American Transplant Congress
Variable Outcomes of Recurrent Autoimmune Diabetes Post Pancreas Transplant Treated with Rituximab
K. Venkatachalam, A. Markwardt, B. Heady, T. Alhamad, A. Malone
Washington University, St. Louis, MO
*Purpose: Demonstrate the outcomes of treatment with rituximab in patients with autoimmune diabetes after pancreas transplant.*Methods: We present the treatment response to rituximab in 3…
2019 American Transplant Congress
Developing a Patient Reported Outcome Measure for Assessment of Calcineurin Inhibitor-Related Symptoms
J. L. Beaumont¹, I. Purnajo¹, M. Polinsky², E. Alemao², M. J. Everly¹
¹Terasaki Research Institute, Los Angeles, CA, ²Bristol Myers Squibb, Princeton, NJ
*Purpose: Calcineurin inhibitor (CNI) therapy has side effects which can potentially impact a patient’s health related quality of life (HRQoL). A standardized measure to assess…
2019 American Transplant Congress
Caregiving in Thoracic Transplantation–A SR/MA
A. A. Rmilah, J. Lau, R. Mendpara, P. Erwin, C. C. Kennedy
Mayo Clinic, Rochester, MN
*Purpose: Caregivers are required for heart and lung transplantation, however, little emphasis is placed on the pre-transplant caregiving experience. Our objective was to perform a…
2019 American Transplant Congress
Post-Transplant Lymphoproliferative Disorders after Living-Donor Liver Transplantation: A Retrospective Cohort Study in 1,900 Cases of Single Center Experience
T. Tajima¹, K. Hata¹, H. Haga², M. Nishikori³, J. Kusakabe¹, I. Tamaki¹, T. Ito¹, T. Kaido¹, A. Takaori-Kondo³, S. Uemoto¹
¹Div. of HBP Surgery and Transplantation, Dept. of Surgery, Kyoto University Graduate School of Medicine, Kyoto, Japan, ²Dept. of Diagnostic Pathology, Kyoto University Hospital, Kyoto, Japan, ³Dept. of Hematology and Oncology, Kyoto University Graduate School of Medicine, Kyoto, Japan
*Purpose: Post-transplant lymphoproliferative disorders (PTLD) is relatively rare but the most common, life-threatening neoplasms after organ transplantation. Because of their heterogeneity from benign to malignant…
2019 American Transplant Congress
Identification of Adult Liver Transplant Recipients Eligible to Participate in an Immunosuppression Withdrawal Trial Employing Non-Invasive Assessments of Allograft Status
J. Vionnet¹, R. Miquel¹, A. Douiri¹, M. Elstad¹, E. Kodela¹, A. Quaglia², J. Wall¹, P. Ruiz Martin¹, E. B. Riani³, J. Leithead⁴, A. Marshall², M. Navasa⁵, P. Ruiz⁵, J. Ferguson⁶, K. Simpson⁷, A. Pascher⁸, E. Jaeckel⁹, R. Bishop¹⁰, F. Nevens¹¹, S. Masson¹², A. Sanchez-Fueyo¹
¹King's College London, London, United Kingdom, ²Royal Free, London, United Kingdom, ³St-Luc, Brussels, Belgium, ⁴Addenbrookes, Cambridge, United Kingdom, ⁵Hospital Clinic, Barcelona, Spain, ⁶Queen Elizabeth, Birmingham, United Kingdom, ⁷Royal Infirmary, Edinburgh, United Kingdom, ⁸Charité, Berlin, Germany, ⁹Hannover Medical School, Hannover, Germany, ¹⁰Leeds NHS Trust, Leeds, United Kingdom, ¹¹UZ Leuven, Leuven, Belgium, ¹²Hepatology, Newcastle, United Kingdom
*Purpose: Liver Immunosuppression Free Trial (LIFT) is a multicentre international prospective randomised controlled trial of biomarker-guided immunosuppression withdrawal in adult liver transplant recipients who meet…
2019 American Transplant Congress
Clinical Trial of Allogeneic Islet Transplantation in the Treatment of Diabetes after Renal Transplantation
W. liang, M. Hu, G. Peng, D. Zhou, C. Zeng, W. Zhou, q. Ye, Z. Wang
Zhongnan Hospital of Wuhan University, Institute of Hepatobiliary Diseases, Wuhan, China
*Purpose: Diabetes after renal transplantation is one of the most serious complications after renal transplantation. It has a serious impact to the survival of kidney…
2019 American Transplant Congress
Ex Vivo Assessment of Marginal Human Kidneys Using Computed Tomography
M. K. Harris¹, J. R. DiRito², H. Liu³, N. Boutagy³, C. Liu⁴, S. Hosgood², D. Mulligan¹, M. L. Nicholson², A. Sinusas³, D. Haakinson¹, G. T. Tietjen¹
¹Surgery, Yale School of Medicine, New Haven, CT, ²Surgery, University of Cambridge, Cambridge, United Kingdom, ³Yale Translational Research Imaging Center, New Haven, CT, ⁴Radiology, Yale School of Medicine, New Haven, CT
*Purpose: Thousands of ‘marginal’ organs are discarded each year despite a severe organ shortage. This has motivated development of new technologies, such as ex vivo…
2019 American Transplant Congress
Combined Thoracic-Liver Transplants Using Normothermic Machine Perfusion for Liver Preservation: A Case Series
M. Rizzari, K. Crombez, S. Nagai, J. Stracke, A. Al-Kurd, K. Collins, A. Yoshida, M. Abouljoud
Henry Ford Transplant Institute, Detroit, MI
*Purpose: There is minimal data describing combined thoracic-liver transplants (tx) with normothermic machine perfusion (NMP) used for liver preservation as the thoracic tx is done.…
2019 American Transplant Congress
Pluripotent Stem Cell Differentiation: Delaying Forward Differentiation Signals Maintains Definitive Endoderm Phenotype for Cellular Transplantation
J. Fair¹, M. M. Shoja¹, N. Liu¹, I. Patrikeev², M. Motamedi², W. S. Fagg¹
¹Surgery, University of Texas Medical Branch, Galveston, TX, ²Opthalmology and Visual Sciences, University of Texas Medical Branch, Galveston, TX
*Purpose: Endodermal precursors (EP), derived in vitro from mouse pluripotent stem cell (PSC) sources, are capable of clinically useful engraftment in the unmodified (quiescent) liver…
2019 American Transplant Congress
Endogenous Erythropoietin is Required for Spontaneous Acceptance of Murine Renal Allografts
J. Horwitz, P. Cravedi, P. Heeger
Icahn School of Medicine at Mount Sinai, NY, NY
*Purpose: B6 recipients spontaneously accept MHC-disparate renal allografts from allogeneic DBA/2 x B6 (H-2d x H-2b) F1 donors via mechanisms that are in part regulatory…